| Document |
Document Title |
|
WO/2014/057078A1 |
The present application relates to compounds of formula (I), wherein R1 to R5 are as defined in claim 1, a pharmaceutical composition thereof and said compounds for use in the treatment of diseases related with the activity of P2X7 recep...
|
|
WO/2014/058078A1 |
Disclosed is a process for preparing dihydro-2H-pyran derivatives of formula I: wherein R1 and R2 are defined herein. The process of the invention provides the compound of formula I in concise cascade reactions and in one pot. The compou...
|
|
WO/2014/040457A1 |
An intermediate of formula (V) used for preparing limaprost of formula (I), preparation method thereof, and preparation method of limaprost therefrom. The present preparation method of limaprost from the intermediate of formula (V) inclu...
|
|
WO/2014/041362A1 |
The present invention relates to a compound which when exposed to ultraviolet-A (UVA) radiation is cleaved to produce a first compound which is a transition metal chelating compound and a second compound which has antioxidant and/or UV a...
|
|
WO/2014/037560A1 |
The invention provides a process to separate levulinic acid from a composition obtained by acid hydrolysis of biomass said process comprising subjecting said composition to solvent-solvent extraction to yield an organic phase comprising ...
|
|
WO/2014/038663A1 |
Provided are: a method for producing a sulfonyl amidine compound, which has an excellent gonadotropin releasing hormone receptor antagonism and is useful as a therapeutic agent for gonadotropin-dependent diseases (for example, prostate c...
|
|
WO/2014/033170A1 |
Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R1, R2 and R4 have the meaning as defined herein. The present invention also relates to pharmaceuti...
|
|
WO/2014/033176A1 |
Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R1, R2 and R4 have the meaning as defined herein. The present invention also relates to processes f...
|
|
WO/2014/028669A1 |
The present invention relates to aryl sulfones and related compounds that are modulators of ROR-gamma receptors. The invention also provides pharmaceutical compositions comprising these modulators, and methods of modulating ROR-gamma rec...
|
|
WO/2014/025679A1 |
The present invention is directed to a process for the preparation of heterocyclic derivatives of formula I (I), wherein J, X, Z, W and R2 are as defined herein using a palladium catalysed aminocarbonylation reaction. Such compounds are ...
|
|
WO/2014/016381A1 |
The invention relates to a crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D- glucopyranos-1 -yl)-benzene and a natural amino acid, to methods for the preparation thereof, as well as to uses thereof for preparing medicaments.
|
|
WO/2014/015054A1 |
Disclosed herein are novel pharmaceutical agents which are useful as integrin receptor antagonists that mediate the pathologic processes of angiogenesis and fibrosis and as such are useful in pharmaceutical compositions and in methods fo...
|
|
WO/2014/006250A1 |
The invention relates to the use of a compound having formula I, in which R1 is an alkenyl group C5-C25 containing one ore more double carbon-carbon bonds, R2 is selected independently from the group consisting of methyl and fluorinated ...
|
|
WO/2013/169651A9 |
A method of making an anti-Markovnikov addition product is carried out by reacting an acid with an alkene or alkyne in a dual catalyst reaction system to the exclusion of oxygen to produce said anti-Markovnikov addition product; the dual...
|
|
WO/2014/002105A1 |
The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use ...
|
|
WO/2013/192352A1 |
The invention provides compounds of formula la, lb and Ic: [Formula Ia, Ib, and Ic] and salts thereof, wherein variables are as described in the specification, as well as compositions comprising a compound of formula Ia-Ic, methods of ma...
|
|
WO/2013/181741A1 |
The present invention relates to compounds having the general Formula I: which absorb UV radiations and protect biological materials as well as non-biological materials from damaging exposure to UV radiations. The present invention also ...
|
|
WO/2013/180140A1 |
The present invention provides a novel dihydroorotic acid dehydrogenase inhibitor that is applicable to various diseases. As an active ingredient, a compound represented by formula (I) (wherein X represents a halogen atom; R1 represents ...
|
|
WO/2013/177243A1 |
A process for making the compound of Formula I utilizes the starting compound, together with sulfilimine and sulfoxide process steps later on.
|
|
WO/2013/160418A1 |
The present invention is directed to novel retinoid-related orphan receptor gamma (RORγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammator...
|
|
WO/2013/161851A1 |
The present invention pertains to a benzamide derivative represented by formula (I), or a pharmaceutically acceptable salt thereof.
|
|
WO/2013/159224A1 |
Certain 2-carbamo(thio)yl-1,3-dioxopropyl derivatives, or the tautomers and pharmacologically acceptable addition salts thereof are found to be toxic to cancer cells, in part, by inhibiting DNA topoisomerase II enzyme making them candida...
|
|
WO/2013/158302A1 |
The invention provides derivatives of DEA which have increased potency and hydrolysis resistance as compared to DEA, and compositions thereof, as well as methods of using these derivatives to promote neurogenesis, neurite growth and/or l...
|
|
WO/2013/152476A1 |
Provided are methods of making compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides synthetic intermediates useful for preparing such compounds.
|
|
WO/2013/152848A1 |
The present invention relates to fucose- and mannose-derived glycomimetics and their general use in prophylaxis or treatment of Pseudomonas aeruginosa infections including respiratory tract infections, urinary tract infections, nosocomia...
|
|
WO/2013/147096A1 |
The present invention provides: a compound represented by formula (I) or a salt thereof; a method for quantitatively analyzing a target substance containing an amino group, which comprises labeling the target substance in at least two sa...
|
|
WO/2013/144394A1 |
Alternariol and alternariol monomethyl ether are two of the toxins produced in greatest amounts by fungi of the family Alternaria. They occur frequently in foodstuffs and continued consumption thereof may have negative effects on human h...
|
|
WO/2013/146539A1 |
According to the present invention, PPARs agonist activity is enhanced in order to improve metabolic syndrome, hyperlipidemia, and diabetes. Provided is a compound having a lactone structure comprising formula (9).
|
|
WO/2013/142812A1 |
The invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and G are as described in the specification, as well as compositions comprising a compound of formula I, methods of...
|
|
WO/2013/134415A1 |
The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides pharmaceutically acceptable compositions containing the compounds and m...
|
|
WO/2013/130792A2 |
Fluorinated prodrug compounds as can be used for selective streptococcal mevalonate pathway inhibition.
|
|
WO/2013/125356A1 |
Provided are: a liquid crystal compound which has high stability with respect to heat, light and the like, high clearing point, low lower limit temperature of the liquid crystal phase, low viscosity, adequate optical anisotropy, large di...
|
|
WO/2013/125777A1 |
The present invention relates to a biosynthetic gene cluster for a chejuenolide of the marine microorganism Hahella chejuensis, and to the function of an enzyme involving the biosynthetic pathway of a chejuenolide coded by the genes. Sin...
|
|
WO/2013/122028A1 |
The purpose of the present invention is to provide an aromatic ring compound exhibiting GPR40 agonist activity. The compound represented by formula (I) (refer to the description for information pertaining to each symbol in the formula) o...
|
|
WO/2013/118907A1 |
An amide compound represented by formula (I) has an excellent pest control effect. (In the formula, Y represents a 3-7 membered saturated heterocyclic ring which contains, as ring-forming component(s), one or more atoms or groups that ar...
|
|
WO/2013/118905A1 |
An amide compound represented by formula (I) has an excellent pest control effect. (In the formula, Y represents a 3-7 membered saturated heterocyclic ring which contains, as ring-forming component(s), one or more atoms or groups that ar...
|
|
WO/2013/073483A9 |
[Problem] To impart significantly improved myo-inositol producing capability, suitable for use in recombinant DNA techniques and synthetic biology methods, to a host microorganism that does not possess an endogenous myo-inositol biosynth...
|
|
WO/2013/106029A1 |
The present application discloses new taxane analogs, intermediates and methods for producing them. The present application is also directed to pharmaceutical formulations comprising abeo-taxanes and methods of treating cancer with the a...
|
|
WO/2013/063679A9 |
Use of Neu1 sialidase inhibitors for the treatment of cancer as a monotherapy or in combination with known chemotherapeutics. Preferably, Neu1 sialidase inhibitors are oseltamivir phosphate or 2-deoxy-2,3-dehydro-N-acetylneuraminic acid ...
|
|
WO/2013/103668A1 |
In accordance with the present invention, there are provided compositions comprising zanamivir and at least one permeability enhancer. The compositions can increase the amount of zanamivir capable of being transported across a cell membr...
|
|
WO/2013/097424A1 |
Provided are a marine streptomyces sp., a compound of pyranosesquiterpenes and a preparation method and the use thereof. Streptomyces sp. SCSIO 01689 was deposited in the China Center for Type Culture Collection (CCTCC) on July 18, 2011,...
|
|
WO/2013/096971A1 |
The discovery of distinct modes of asymmetric catalysis has the potential to rapidly advance chemists' ability to build enantioenriched molecules. As an example, the use of chiral cation salts as phase-transfer catalysts for anionic reag...
|
|
WO/2013/092941A1 |
Compounds of the formula (I) or pharmaceutically acceptable salts thereof, wherein m, n, A, X1, X2, X3, X4, R1, R2, R3a, R3b, R4a and R4b are as defined herein. Also disclosed are methods of making the compounds and using the compounds f...
|
|
WO/2013/093320A1 |
The invention relates to the use of 1-aryl-2-aryloxyethane compounds with formula I, wherein n and m are equal to 0 or 1, provided that n+m=1, R1 and R2 particularly representing hydrogen atoms, R3 and R4 particularly representing hydrog...
|
|
WO/2013/089168A1 |
The present invention provides a method for producing a neuraminic acid derivative. A method for producing a compound represented by formula (I) [wherein R1 represents a C1-C19 alkyl group] or a pharmacologically acceptable salt thereof ...
|
|
WO/2013/088972A1 |
Provided is a compound represented by general formula (1). (1) In general formula (1), R1 is either a protecting group for a hydroxyl group or a hydrogen atom. R2 is either a methyl group or an ethyl group.
|
|
WO/2013/079501A1 |
The present invention is directed to crystalline dapagliflozin hydrate and a process for obtaining the same. Dapagliflozin has the structure of formula (I).
|
|
WO/2013/079708A1 |
The present invention relates to a compound of formula (I): wherein: X is methyl or chlorine; R1 is methyl or chlorine; R2 is hydrogen, methyl, ethyl, n-propyl, cyclopropyl, vinyl, ethynyl, fluorine, chlorine, bromine, methoxy, ethoxy or...
|
|
WO/2013/075400A1 |
Disclosed is a liquid crystal compound. The compound has a general structural formula as shown by formula I. Such a compound has good thermal and UV stability, large positive dielectric anisotropy △ε, and can achieve a low threshold v...
|
|
WO/2013/070911A1 |
The invention features novel compounds useful for the treatment or prevention of cystic fibrosis. Further, the invention also relates to methods, kits and packaged compositions for the treatment or prevention of cystic fibrosis in a subj...
|
